There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Verastem (NASDAQ: VSTM), Synergy Pharmaceuticals Inc (NASDAQ: SGYP) and Aerie Pharma (NASDAQ: AERI) with bullish sentiments.
Verastem (NASDAQ: VSTM)
In a report released today, Leah R. Cann from Oppenheimer maintained a Buy rating on Verastem (NASDAQ: VSTM), with a price target of $15. The company’s shares opened today at $5.38, close to its 52-week high of $5.90.
“Verastem has presented positive data for its two lead assets, Duvelisib and Defactinib; and has entered into a partnering agreement in Japan. Positive DUO study crossover data at ASCO support our expectations for Duvelisib adoption. The Defactinib data in pancreatic cancer presented at ASCO are early, but encouraging in this difficult to treat setting. In addition, the licensing deal for Duvelisib in Japan could provide upside to our outlook.”
According to TipRanks.com, Cann is a 5-star analyst with an average return of 18.2% and a 61.6% success rate. Cann covers the Healthcare sector, focusing on stocks such as Miragen Therapeutics Inc, CytomX Therapeutics Inc, and Crispr Therapeutics AG.
Verastem has an analyst consensus of Strong Buy, with a price target consensus of $13.33.
Synergy Pharmaceuticals Inc (NASDAQ: SGYP)
In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Synergy Pharmaceuticals Inc (NASDAQ: SGYP), with a price target of $13. The company’s shares opened today at $1.59, close to its 52-week low of $1.43.
According to TipRanks.com, Newman is a 5-star analyst with an average return of 19.1% and a 46.7% success rate. Newman covers the Healthcare sector, focusing on stocks such as Hutchison China MediTech Ltd, Aileron Therapeutics Inc, and Atara Biotherapeutics.
Synergy Pharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $8.25.
Aerie Pharma (NASDAQ: AERI)
“We view strong payer acceptance, coupled with early Medicare wins, as a solid positive sign for Rhopressa performance and believe management’s current product revenue guidance of $20 mm to $30 mm for 2018 is handily achievable. Rhopressa already available to 70% of commercially-covered lives. Just a little over a month post-launch, Aerie indicated that Rhopressa is on formulary for 70% of commercially-covered lives (up from 1Q/18 commentary that it was covered for a “majority” of covered lives). Around 25% of these patients are covered at tier 2; commercial patients can use a copay card to get to a $20 copay. The 30% of commercially-covered lives where Rhopressa is not on formulary can use the card to get to a $50 monthly copay.”
According to TipRanks.com, Steadman is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -4.1% and a 38.5% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Correvio Pharma Corp.
Currently, the analyst consensus on Aerie Pharma is Strong Buy and the average price target is $81.75, representing a 44.8% upside.
In a report issued on June 1, Mizuho Securities also assigned a Buy rating to the stock with a $77 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.